Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ReShape Lifesciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda ReShape Lifesciences için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.5%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak ReShape Lifesciences yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:RSLS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	8	-9	-9	-9	N/A
3/31/2024	8	-11	-14	-14	N/A
12/31/2023	9	-11	-17	-17	N/A
9/30/2023	10	-26	-17	-17	N/A
6/30/2023	10	-35	-20	-20	N/A
3/31/2023	11	-41	-20	-20	N/A
12/31/2022	11	-46	-22	-22	N/A
9/30/2022	11	-66	-23	-22	N/A
6/30/2022	12	-72	-25	-25	N/A
3/31/2022	13	-66	-21	-21	N/A
12/31/2021	14	-63	-16	-15	N/A
9/30/2021	14	-35	-14	-14	N/A
6/30/2021	14	-22	-7	-7	N/A
3/31/2021	12	-22	-8	-7	N/A
12/31/2020	11	-22	-9	-9	N/A
9/30/2020	12	-38	-8	-8	N/A
6/30/2020	12	-62	-12	-11	N/A
3/31/2020	15	-74	-12	-12	N/A
12/31/2019	15	-74	-14	-14	N/A
9/30/2019	11	-52	-20	-20	N/A
6/30/2019	8	-28	-20	-20	N/A
3/31/2019	4	-35	-24	-24	N/A
12/31/2018	1	-38	-28	-27	N/A
9/30/2018	0	-42	-29	-29	N/A
6/30/2018	1	-47	-30	-30	N/A
3/31/2018	1	-30	N/A	-29	N/A
12/31/2017	1	-30	N/A	-25	N/A
9/30/2017	1	-29	N/A	-19	N/A
6/30/2017	1	-25	N/A	-18	N/A
3/31/2017	1	-23	N/A	-18	N/A
12/31/2016	1	-23	N/A	-21	N/A
9/30/2016	1	-26	N/A	-22	N/A
6/30/2016	1	-23	N/A	-24	N/A
3/31/2016	0	-26	N/A	-24	N/A
12/31/2015	0	-25	N/A	-23	N/A
9/30/2015	0	-25	N/A	-22	N/A
6/30/2015	0	-26	N/A	-20	N/A
3/31/2015	N/A	-27	N/A	-19	N/A
12/31/2014	N/A	-26	N/A	-19	N/A
9/30/2014	N/A	-27	N/A	-19	N/A
6/30/2014	N/A	-27	N/A	-19	N/A
3/31/2014	N/A	-26	N/A	-19	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RSLS 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.5% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: RSLS 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: RSLS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: RSLS şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: RSLS şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RSLS 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

ReShape Lifesciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

Consensus EPS estimates upgraded to US$16.50 loss

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Recent updates

Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023)

ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin